LifeStance Health Group, Inc. (LFST) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 14, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the LFST SEC filings page.
LifeStance Health Group, Inc. (LFST) reported $1.6B in revenue over the twelve months to Jun 30, 2026, up 20.4% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The business has moved from heavy losses to modest profitability, with cash generation improving faster than the balance sheet's leverage.
The key transition is not merely crossing into profit: FY2025 operating margin reached1.7% alongside operating cash flow of$146.2M , so reported earnings and cash generation are pointing in the same direction.
Despite SG&A rising to
Cash conversion strengthened: FY2025 operating cash flow of
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of LifeStance Health Group, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
LifeStance Health Group, Inc. has an operating margin of 1.7%, meaning the company retains $2 of operating profit per $100 of revenue. This results in a moderate score of 30/100, indicating healthy but not exceptional operating efficiency. This is up from -2.5% the prior year.
LifeStance Health Group, Inc.'s revenue grew 13.9% year-over-year to $1.4B, a solid pace of expansion. This earns a growth score of 78/100.
LifeStance Health Group, Inc. carries a low D/E ratio of 0.17, meaning only $0.17 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 71/100, indicating a strong balance sheet with room for future borrowing.
LifeStance Health Group, Inc.'s current ratio of 1.65 indicates adequate short-term liquidity, earning a score of 48/100. The company can meet its near-term obligations, though with limited headroom.
LifeStance Health Group, Inc. has a free cash flow margin of 7.7%, earning a moderate score of 44/100. The company generates positive cash flow after capital investments, but with room for improvement.
LifeStance Health Group, Inc.'s ROE of 0.6% shows moderate profitability relative to equity, earning a score of 32/100. This is up from -4.0% the prior year.
LifeStance Health Group, Inc. scores 4.37, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($4.7B) relative to total liabilities ($682.9M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
LifeStance Health Group, Inc. passes 7 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, LifeStance Health Group, Inc. generates $15.12 in operating cash flow ($146.2M OCF vs $9.7M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
LifeStance Health Group, Inc. earns $2.07 in operating income for every $1 of interest expense ($24.1M vs $11.7M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.
Key Financial Metrics
Earnings & Revenue
LifeStance Health Group, Inc. generated $435.4M in revenue in Q2 2026. This represents an increase of 26.1% from the same quarter a year earlier. Against the prior quarter it is up 7.9%.
LifeStance Health Group, Inc.'s EBITDA was $42.0M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 445.7% from the same quarter a year earlier. Against the prior quarter it is up 28.5%.
LifeStance Health Group, Inc. reported $23.6M in net income in Q2 2026. This represents an increase of 722.8% from the same quarter a year earlier. Against the prior quarter it is up 65.8%.
LifeStance Health Group, Inc. earned $0.06 per diluted share (EPS) in Q2 2026. This represents an increase of 700.0% from the same quarter a year earlier. Against the prior quarter it is up 50.0%.
Cash & Balance Sheet
LifeStance Health Group, Inc. generated $87.9M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 55.2% from the same quarter a year earlier. Against the prior quarter it is up 293.5%.
LifeStance Health Group, Inc. held $225.9M in cash against $259.0M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
LifeStance Health Group, Inc.'s operating margin was 7.0% in Q2 2026, reflecting core business profitability. This is up 7.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.5 percentage points.
LifeStance Health Group, Inc.'s net profit margin was 5.4% in Q2 2026, showing the share of revenue converted to profit. This is up 6.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.9 percentage points.
LifeStance Health Group, Inc.'s ROE was 1.6% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 1.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.6 percentage points.
Not reported for Q2 2026.
Capital Allocation
LifeStance Health Group, Inc. spent $48.5M on share buybacks in Q2 2026, returning capital to shareholders by reducing shares outstanding. Against the prior quarter it is down 1.2%.
LifeStance Health Group, Inc. invested $12.0M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 54.7% from the same quarter a year earlier. Against the prior quarter it is up 11.4%.
Not reported for Q2 2026.
LFST Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $435.4M+26.1% | $403.5M+21.2% | $382.2M+17.4% | $363.8M+16.3% | $345.3M+10.6% | $333.0M+10.8% | $325.5M+16.0% | $312.7M+19.0% |
| SG&A Expenses | $108.1M+11.1% | $100.3M+6.2% | $94.8M+1.1% | $95.6M+12.1% | $97.4M+2.3% | $94.4M+6.2% | $93.7M+0.4% | $85.3M-34.9% |
| Operating Income | $30.7M+1139.1% | $22.3M+1289.3% | $18.1M+1607.6% | $7.4M+15666.0% | -$3.0M+81.5% | $1.6M+109.6% | $1.1M+103.3% | $47K+100.1% |
| EBITDA | $42.0M+445.7% | $32.6M+174.5% | $28.4M+154.4% | $17.8M+69.8% | $7.7M+232.2% | $11.9M+276.2% | $11.2M+149.5% | $10.5M+116.1% |
| Interest Expense | $2.6M-9.2% | $1.8M-41.7% | $2.9M-69.4% | $2.8M-48.0% | $2.9M-50.2% | $3.1M-47.9% | $9.4M+69.8% | $5.4M-1.2% |
| Income Tax | $3.8M+278.8% | $5.5M+353.2% | $3.5M+300.4% | $3.5M+507.8% | -$2.2M-427.9% | -$2.2M-700.3% | -$1.8M-126.6% | $575K+103.5% |
| Net Income | $23.6M+722.8% | $14.2M+1908.9% | $11.7M+184.7% | $1.1M+51.9% | -$3.8M+83.7% | $709K+103.4% | -$13.8M+69.4% | $709K+101.2% |
| EPS (Basic) | $0.06+700.0% | $0.04 | $0.04+300.0% | $0.00+100.0% | -$0.01+83.3% | $0.00+100.0% | -$0.02+83.3% | -$0.02+88.2% |
| EPS (Diluted) | $0.06+700.0% | $0.04 | $0.03 | $0.00+100.0% | -$0.01+83.3% | $0.00+100.0% | -$0.02 | -$0.02+88.2% |
| Diluted Shares (Avg) | 387M+0.1% | 395M+1.1% | N/A | 389M+2.2% | 387M+1.9% | 391M+3.8% | N/A | 380M+2.1% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses.
LFST Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.2B+1.6% | $2.1B+2.0% | $2.2B+4.0% | $2.1B+1.9% | $2.1B+1.3% | $2.1B-0.1% | $2.1B+0.4% | $2.1B-3.1% |
| Current Assets | $378.0M+5.3% | $355.9M+16.8% | $416.2M+33.2% | $360.4M+25.6% | $358.8M+29.2% | $304.6M+24.8% | $312.5M+38.4% | $287.0M+8.6% |
| Cash & Equivalents | $225.9M+19.6% | $194.8M+45.0% | $248.6M+60.9% | $203.9M+98.7% | $188.9M+117.2% | $134.3M+171.7% | $154.6M+96.1% | $102.6M+140.9% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Receivable | $111.0M-14.3% | $122.9M-12.4% | $95.7M-27.4% | $121.1M-23.4% | $129.5M-22.6% | $140.4M-20.2% | $131.8M+5.1% | $158.2M+5.6% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $1.3B+0.9% | $1.3B+0.3% | $1.3B0.0% | $1.3B0.0% | $1.3B0.0% | $1.3B0.0% | $1.3B0.0% | $1.3B0.0% |
| Total Liabilities | $704.3M+4.7% | $668.5M+3.2% | $682.9M+1.6% | $656.2M-2.2% | $672.9M-2.4% | $647.6M-4.4% | $672.0M-1.3% | $670.8M-6.8% |
| Current Liabilities | $274.8M+13.4% | $239.7M+15.6% | $252.0M+10.1% | $228.6M+5.1% | $242.3M+6.4% | $207.4M0.0% | $228.9M+12.8% | $217.5M-9.7% |
| Non-Current Liabilities | $429.6M-0.2% | $428.7M-2.6% | $431.0M-2.7% | $427.7M-5.7% | $430.6M-6.7% | $440.2M-6.3% | $443.1M-7.3% | $453.3M-5.4% |
| Long-Term Debt | $259.0M-5.1% | $262.5M-5.0% | $265.9M-5.0% | $269.4M-3.5% | $272.9M-2.4% | $276.3M-1.3% | $279.8M-0.2% | $279.1M+12.4% |
| Total Equity | $1.5B+0.2% | $1.5B+1.4% | $1.5B+5.2% | $1.5B+3.9% | $1.5B+3.1% | $1.5B+2.0% | $1.4B+1.2% | $1.4B-1.2% |
| Retained Earnings | -$770.8M+6.2% | -$794.4M+2.8% | -$808.6M+1.2% | -$820.3M-1.1% | -$821.4M-2.0% | -$817.6M-4.6% | -$818.3M-7.5% | -$811.2M-13.3% |
Not reported in any period shown, so not listed: Inventory.
LFST Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $99.9M+55.2% | $33.1M+1170.8% | $57.6M-7.6% | $27.3M+20.1% | $64.4M+46.2% | -$3.1M+85.8% | $62.3M+271.0% | $22.7M+189.6% |
| Depreciation & Amortization | $11.3M+6.3% | $10.4M+0.7% | $10.3M+2.3% | $10.3M-0.6% | $10.6M+5.0% | $10.3M+2.7% | $10.1M+4.6% | $10.4M+10.2% |
| Stock-Based Compensation | N/A | $15.2M-18.2% | N/A | N/A | N/A | $18.6M-9.7% | N/A | N/A |
| Capital Expenditures | $12.0M+54.7% | $10.8M+50.2% | $10.9M+73.2% | $10.3M+103.7% | $7.8M+51.8% | $7.2M+40.4% | $6.3M-44.8% | $5.1M-48.4% |
| Free Cash Flow | $87.9M+55.2% | $22.3M+317.8% | $46.6M-16.7% | $17.0M-3.8% | $56.6M+45.4% | -$10.3M+61.9% | $56.0M+941.0% | $17.7M+150.3% |
| Investing Cash Flow | -$17.9M-130.7% | -$13.9M-94.1% | -$10.9M-73.2% | -$10.3M-103.7% | -$7.8M-51.8% | -$7.2M-40.4% | -$6.3M+44.8% | -$5.1M+48.4% |
| Financing Cash Flow | -$50.9M-2384.3% | -$73.0M-632.3% | -$1.9M+52.9% | -$2.0M+0.1% | -$2.0M-43.0% | -$10.0M-310.3% | -$4.1M-113.2% | -$2.0M-9.5% |
| Share Buybacks | $48.5M | $49.1M | N/A | N/A | $0 | $0 | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid.
LFST Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | 7.0%+7.9pp | 5.5%+5.0pp | 4.7%+4.4pp | 2.0%+2.0pp | -0.9%+4.3pp | 0.5%+6.1pp | 0.3%+11.8pp | 0.0%+28.3pp |
| Net Margin | 5.4%+6.5pp | 3.5%+3.3pp | 3.0%+7.3pp | 0.3%+0.1pp | -1.1%+6.3pp | 0.2%+7.2pp | -4.2%+11.8pp | 0.2%+23.6pp |
| Return on Equity | 1.6%+1.9pp | 1.0%+0.9pp | 0.8%+1.7pp | 0.1%0.0pp | -0.3%+1.4pp | 0.1%+1.5pp | -1.0%+2.2pp | 0.1%+4.3pp |
| Return on Assets | 1.1%+1.3pp | 0.7%+0.6pp | 0.5%+1.2pp | 0.1%0.0pp | -0.2%+0.9pp | 0.0%+1.0pp | -0.7%+1.5pp | 0.0%+2.9pp |
| Current Ratio | 1.38-0.1x | 1.480.0x | 1.65+0.3x | 1.58+0.3x | 1.48+0.3x | 1.47+0.3x | 1.37+0.3x | 1.32+0.2x |
| Debt-to-Equity | 0.180.0x | 0.180.0x | 0.170.0x | 0.180.0x | 0.190.0x | 0.190.0x | 0.190.0x | 0.190.0x |
| Asset Turnover | 0.200.0x | 0.190.0x | 0.170.0x | 0.170.0x | 0.160.0x | 0.160.0x | 0.150.0x | 0.150.0x |
| FCF Margin | 20.2%+3.8pp | 5.5%+8.6pp | 12.2%-5.0pp | 4.7%-1.0pp | 16.4%+3.9pp | -3.1%+5.9pp | 17.2%+15.3pp | 5.7%+19.0pp |
Not reported in any period shown, so not listed: Gross Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| LifeStance Health Group, Inc. LFST | FY2025 | $1.4B | $9.7M | 0.7% | $4.7B | 51/100 |
| Acadia Healthcare Company, Inc. ACHC | FY2025 | $3.3B | -$1.1B | -33.3% | $2.8B | 25/100 |
| Addus HomeCare Corp. ADUS | FY2025 | $1.4B | $95.9M | 6.7% | $2.2B | 68/100 |
| Surgery Partners, Inc. SGRY | FY2025 | $3.3B | -$77.9M | -2.4% | $1.9B | 54/100 |
| Concentra Group Holdings Parent, Inc. CON | FY2025 | $2.2B | $166.4M | 7.7% | $4.8B | 57/100 |
Where LifeStance Health Group, Inc. Ranks
Frequently Asked Questions
What is LifeStance Health Group, Inc.'s annual revenue?
LifeStance Health Group, Inc. (LFST) reported $1.4B in total revenue for fiscal year 2025. This represents a 13.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is LifeStance Health Group, Inc.'s revenue growing?
LifeStance Health Group, Inc. (LFST) revenue grew by 13.9% year-over-year, from $1.3B to $1.4B in fiscal year 2025.
Is LifeStance Health Group, Inc. profitable?
Yes, LifeStance Health Group, Inc. (LFST) reported a net income of $9.7M in fiscal year 2025, with a net profit margin of 0.7%.
What is LifeStance Health Group, Inc.'s EBITDA?
LifeStance Health Group, Inc. (LFST) had EBITDA of $65.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does LifeStance Health Group, Inc. have?
As of fiscal year 2025, LifeStance Health Group, Inc. (LFST) had $248.6M in cash and equivalents against $265.9M in long-term debt.
What is LifeStance Health Group, Inc.'s operating margin?
LifeStance Health Group, Inc. (LFST) had an operating margin of 1.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is LifeStance Health Group, Inc.'s net profit margin?
LifeStance Health Group, Inc. (LFST) had a net profit margin of 0.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is LifeStance Health Group, Inc.'s return on equity (ROE)?
LifeStance Health Group, Inc. (LFST) has a return on equity of 0.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is LifeStance Health Group, Inc.'s free cash flow?
LifeStance Health Group, Inc. (LFST) generated $110.0M in free cash flow during fiscal year 2025. This represents a 28.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is LifeStance Health Group, Inc.'s operating cash flow?
LifeStance Health Group, Inc. (LFST) generated $146.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are LifeStance Health Group, Inc.'s total assets?
LifeStance Health Group, Inc. (LFST) had $2.2B in total assets as of fiscal year 2025, including both current and long-term assets.
What are LifeStance Health Group, Inc.'s capital expenditures?
LifeStance Health Group, Inc. (LFST) invested $36.1M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is LifeStance Health Group, Inc.'s current ratio?
LifeStance Health Group, Inc. (LFST) had a current ratio of 1.65 as of fiscal year 2025, which is generally considered healthy.
What is LifeStance Health Group, Inc.'s debt-to-equity ratio?
LifeStance Health Group, Inc. (LFST) had a debt-to-equity ratio of 0.17 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is LifeStance Health Group, Inc.'s return on assets (ROA)?
LifeStance Health Group, Inc. (LFST) had a return on assets of 0.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is LifeStance Health Group, Inc.'s P/E ratio?
LifeStance Health Group, Inc. (LFST) trades at 92.6x earnings, its market capitalization divided by net income of $50.6M net income, trailing 12 months to June 30, 2026. The market capitalization is $4.7B as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is LifeStance Health Group, Inc.'s price-to-sales ratio?
LifeStance Health Group, Inc. (LFST) trades at 3.0x sales, its market capitalization divided by revenue of $1.6B revenue, trailing 12 months to June 30, 2026. The market capitalization is $4.7B as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is LifeStance Health Group, Inc.'s Altman Z-Score?
LifeStance Health Group, Inc. (LFST) has an Altman Z-Score of 4.37, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is LifeStance Health Group, Inc.'s Piotroski F-Score?
LifeStance Health Group, Inc. (LFST) has a Piotroski F-Score of 7 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are LifeStance Health Group, Inc.'s earnings high quality?
LifeStance Health Group, Inc. (LFST) has an earnings quality ratio of 15.12x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can LifeStance Health Group, Inc. cover its interest payments?
LifeStance Health Group, Inc. (LFST) has an interest coverage ratio of 2.07x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is LifeStance Health Group, Inc.?
LifeStance Health Group, Inc. (LFST) scores 51 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.